| EYA4 promotes breast cancer progression and metastasis through its role in replication stress avoidance. | EYA4 promotes breast cancer progression and metastasis through its role in replication stress avoidance.
de la Peña Avalos B, Tropée R, Duijf PHG, Dray E., Free PMC Article | 10/5/2023 |
| Aberrant DNA methylation and expression of EYA4 in gastric cardia intestinal metaplasia. | Aberrant DNA methylation and expression of EYA4 in gastric cardia intestinal metaplasia.
Li C, Liu Z, Xu G, Wu S, Peng Y, Wu R, Zhao S, Liao X, Lin R., Free PMC Article | 12/10/2022 |
| Identification of a novel CNV at the EYA4 gene in a Chinese family with autosomal dominant nonsyndromic hearing loss. | Identification of a novel CNV at the EYA4 gene in a Chinese family with autosomal dominant nonsyndromic hearing loss.
Zhang W, Song J, Tong B, Ma M, Guo L, Yuan Y, Yang J., Free PMC Article | 05/28/2022 |
| Identification of a Novel Copy Number Variation of EYA4 Causing Autosomal Dominant Non-syndromic Hearing Loss. | Identification of a Novel Copy Number Variation of EYA4 Causing Autosomal Dominant Non-syndromic Hearing Loss.
Ishino T, Ogawa Y, Sonoyama T, Taruya T, Kono T, Hamamoto T, Ueda T, Takeno S, Moteki H, Nishio SY, Usami SI, Nagano Y, Yoshimura A, Yoshikawa K, Kato M, Ichimoto M, Watanabe R. | 09/11/2021 |
| Prognostic Role of EYA4 in Lower Grade Glioma with IDH1 Mutation and 1p19q Co-Deletion. | Prognostic Role of EYA4 in Lower Grade Glioma with IDH1 Mutation and 1p19q Co-Deletion.
Zhu J, Hu LB, Zhao YP, Zhang YQ. | 08/14/2021 |
| Early truncation of the N-terminal variable region of EYA4 gene causes dominant hearing loss without cardiac phenotype. | Early truncation of the N-terminal variable region of EYA4 gene causes dominant hearing loss without cardiac phenotype.
Mi Y, Liu D, Zeng B, Tian Y, Zhang H, Chen B, Zhang J, Xue H, Tang W, Zhao Y, Xu H., Free PMC Article | 08/7/2021 |
| Genome-first approach to rare EYA4 variants and cardio-auditory phenotypes in adults. | Genome-first approach to rare EYA4 variants and cardio-auditory phenotypes in adults.
Ahmadmehrabi S, Li B, Park J, Devkota B, Vujkovic M, Ko YA, Van Wagoner D, Tang WHW, Krantz I, Ritchie M, Regeneron Genetics Center, Brant J, Ruckenstein MJ, Epstein DJ, Rader DJ. | 05/15/2021 |
| Insights into the pathophysiology of DFNA10 hearing loss associated with novel EYA4 variants. | Insights into the pathophysiology of DFNA10 hearing loss associated with novel EYA4 variants.
Morín M, Borreguero L, Booth KT, Lachgar M, Huygen P, Villamar M, Mayo F, Barrio LC, Santos Serrão de Castro L, Morales C, Del Castillo I, Arellano B, Tellería D, Smith RJH, Azaiez H, Moreno Pelayo MA., Free PMC Article | 12/5/2020 |
| Prevalence and clinical features of hearing loss caused by EYA4 variants. | Prevalence and clinical features of hearing loss caused by EYA4 variants.
Shinagawa J, Moteki H, Nishio SY, Ohyama K, Otsuki K, Iwasaki S, Masuda S, Oshikawa C, Ohta Y, Arai Y, Takahashi M, Sakuma N, Abe S, Sakurai Y, Sakaguchi H, Ishino T, Uehara N, Usami SI., Free PMC Article | 11/21/2020 |
| EYA4 is a novel tumour suppressor in HCC and a new prognostic biomarker and therapeutic target in HCC. | EYA4 serves as a prognostic biomarker in hepatocellular carcinoma and suppresses tumour angiogenesis and metastasis.
Gu F, Yuan S, Liu L, Zhu P, Yang Y, Pan Z, Zhou W., Free PMC Article | 08/1/2020 |
| Result show that EYA4 expression is regulated by miR626 which targets its 3'UTR in bladder cancer cells. | Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis.
Dong W, Bi J, Liu H, Yan D, He Q, Zhou Q, Wang Q, Xie R, Su Y, Yang M, Lin T, Huang J., Free PMC Article | 04/18/2020 |
| Study reports that EYA4 suppressed hepatocellular carcinoma (HCC) tumor cell growth by reducing the nuclear translocation of beta-catenin by dephosphorylation at Ser552, thereby suppressing the transcription of MYCBP which was induced by beta-catenin/LEF1 binding to the promoter of MYCBP. | EYA4 inhibits hepatocellular carcinoma by repressing MYCBP by dephosphorylating β-catenin at Ser552.
Zhu XX, Li JH, Cai JP, Hou X, Huang CS, Huang XT, Wang JQ, Li SJ, Xu QC, Yin XY., Free PMC Article | 10/12/2019 |
| the novel missense mutation c.1855T>G (p.W619G) in EYA4 causing autosomal dominant non-syndromic hearing impairment in the selected Chinese family, was identified. | Identification of a novel missense eya4 mutation causing autosomal dominant non‑syndromic hearing loss in a chinese family.
Xiao SY, Qu J, Zhang Q, Ao T, Zhang J, Zhang RH. | 05/25/2019 |
| Findings identified eyes absent homolog 4 (EYA4) as a tumor suppressor that disrupts aberrant activation of the nuclear factor kappa B (NF-kappaB)/RAP1 protein signaling pathway and thus orchestrates a physiological impediment to hepatocellular carcinoma (HCC) growth and invasion. | EYA4 inhibits hepatocellular carcinoma growth and invasion by suppressing NF-κB-dependent RAP1 transactivation.
Mo SJ, Hou X, Hao XY, Cai JP, Liu X, Chen W, Chen D, Yin XY., Free PMC Article | 03/2/2019 |
| Overexpression of EYA4 enhanced glioma cell proliferation, and EYA4 suppressed the expression of p27Kip1 directly in these cells. | EYA4 Promotes Cell Proliferation Through Downregulation of p27Kip1 in Glioma.
Li Z, Qiu R, Qiu X, Tian T. | 10/20/2018 |
| Although the clinical patient outcome of our 38 Colorectal Cancer patients was not associated with EYA4 promoter hypermethylation, the high frequency of this methylation and its high sensitivity and specificity to neoplastic cells may qualify EYA4 promoter methylation as a potential candidate screening marker in Iranian population and may help to improve early detection of CRC. | Promoter Hypermethylation of the Eyes Absent 4 Gene is a Tumor-Specific Epigenetic Biomarker in Iranian Colorectal Cancer Patients.
Barati Bagerabad M, Tavakolian S, Abbaszadegan MR, Kerachian MA. | 07/14/2018 |
| Eyes absent homolog 4 (Drosophila) protein (EYA4) is frequently hypermethylated in esophageal squamous cell carcinoma (ESCC) and may function as a tumor suppressor gene in the development of ESCC. | Aberrant methylation of EYA4 promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma.
Luo M, Li Y, Shi X, Yang W, Zhou F, Sun N, He J., Free PMC Article | 06/23/2018 |
| identified novel EYA4 mutation can be considered responsible of the hearing loss observed in the proband and her father, while a dual molecular diagnosis was reached in the relatives co-segregating the EYA4 and the PAX3 mutations | A novel mutation of the EYA4 gene associated with post-lingual hearing loss in a proband is co-segregating with a novel PAX3 mutation in two congenitally deaf family members.
Cesca F, Bettella E, Polli R, Cama E, Scimemi P, Santarelli R, Murgia A. | 03/10/2018 |
| EYA4 hypermethylation is associated with colorectal cancer. | Genome-wide methylation analysis identifies a core set of hypermethylated genes in CIMP-H colorectal cancer.
McInnes T, Zou D, Rao DS, Munro FM, Phillips VL, McCall JL, Black MA, Reeve AE, Guilford PJ., Free PMC Article | 11/4/2017 |
| EYA4 functions as tumor suppressor gene in pancreatic ductal adenocarcinoma via repressing beta-catenin/ID2 activation, and was an independent prognostic factor in PDAC. | EYA4 functions as tumor suppressor gene and prognostic marker in pancreatic ductal adenocarcinoma through β-catenin/ID2 pathway.
Mo SJ, Liu X, Hao XY, Chen W, Zhang KS, Cai JP, Lai JM, Liang LJ, Yin XY. | 07/29/2017 |
| Low expression of EYA4 is associated with oral cancer. | Epigenetic mediated silencing of EYA4 contributes to tumorigenesis in oral dysplastic cells.
Towle R, Truong D, Garnis C. | 07/22/2017 |
| We discovered two genome-wide significant SNPs. The first was novel and near ISG20. The second was in TRIOBP, a gene previously associated with prelingual nonsyndromic hearing loss. Motivated by our TRIOBP results, we also looked at exons in known hearing loss genes, and identified two additional SNPs, rs2877561 in ILDR1 and rs9493672 in EYA4 (at a significance threshold adjusted for number of SNPs in those regions). | A Large Genome-Wide Association Study of Age-Related Hearing Impairment Using Electronic Health Records.
Hoffmann TJ, Keats BJ, Yoshikawa N, Schaefer C, Risch N, Lustig LR., Free PMC Article | 05/13/2017 |
| Locus polymorphism of rs3813346 was associated with the risk of developing noise-induced hearing loss in the dominance model, the codominance model and the addictive model. Generalized multiple dimensionality reduction indicated that the combined interaction of the 2 loci-rs3813346 and rs9493627-significantly affected the incidence of noise-induced hearing loss. | Genetic variation in EYA4 on the risk of noise-induced hearing loss in Chinese steelworks firm sample.
Yang Q, Xu X, Jiao J, Zheng Y, He L, Yu S, Gu G, Chen G, Zhou W, Wu H, Li Y, Zhang H, Zhang Z. | 05/13/2017 |
| Up to now, merely 7 loci have been linked to mid-frequency hearing loss. Only four genetic mid-frequency deafness genes, namely, DFNA10 (EYA4), DFNA8/12 (TECTA), DFNA13 (COL11A2), DFNA44 (CCDC50), have been reported to date. [review] | Research progress in pathogenic genes of hereditary non-syndromic mid-frequency deafness.
Xia W, Liu F, Ma D. | 04/22/2017 |
| study identified EYA4 gene as targets for AML1-ETO and indicated it as a novel tumor suppressor gene. In addition, we provided evidence that EYA4 gene might be a novel therapeutic target and a potential candidate for treating AML1-ETO+ t (8;21) AML. | Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia.
Huang S, Jiang MM, Chen GF, Qian K, Gao HH, Guan W, Shi JL, Liu AQ, Liu J, Wang BH, Li YH, Yu L., Free PMC Article | 03/18/2017 |